/Health Tech Forward Event 2024
Invite

Pending to review

Not sure yet

Interested

Not interested

Get more companies

Download list

Company
Relevance
Description
Subspaces
HQ Location
Founded
Employees
Total Funding Raised
Funding Status
Received on
Picks for your space
Sensius is focused on establishing thermotherapy as a key treatment modality for cancer patients alongside radiotherapy, surgery, chemotherapy, and immunotherapy. Sensius mission is to deliver optimized radiotherapy treatment outcomes for patients with head and neck cancer, by balancing efficacy with quality of life.
  • General Match
Rotterdam (Netherlands)20151 - 10$14.06MGrant, $1.82M, February 15, 2023
1 year ago
We provide people, professionals and organizations with artificial intelligence tools that help solve medical and health related challenges. By partnering with hospitals and other institutions in the healthcare domain we bring innovative solutions to real life problems. We forge long-term relationships with our partners to help them unlock the intelligence hidden in their data.
  • General Match
Amsterdam (Netherlands)201711 - 50$5.03MVenture - Series Unknown, $2.67M, November 27, 2025
1 year ago
For 1B people with no access to proper eye care, we provide a mobile app allowing them to test their eyes objectively just with their smartphones - by analyzing photos of their eyes with AI. So that they can get their eye test result in a matter of minutes and see clearly again. Unlike traditional methods that rely on subjective feedback, costly hardware, and in-person visits, we offer a fully mobile, hardware-free solution based on objective testing and neural networks.
  • General Match
Wroclaw (Poland)201911 - 50$681.88KGrant, June 17, 2024
1 year ago
Intelligent Patient History and Assessments AI guided diagnosis, disease management, and navigation for patients and healthcare providers and health plans,
  • General Match
Cambridge, MA (United States)20211 - 10NA
1 year ago
We work on AI powered neurofeedback solution for kids with ADHD and ASD. Our Mission is to provide neurodivergent children the opportunity for the brighter future. Our Vision is to create a world where neurodivergent children can achieve their full potential, supported by the most advanced, personalized, and compassionate care, ensuring every child has the opportunity to thrive in their own unique way.
  • General Match
Brooklyn (United States)201811 - 50Convertible Note, September 22, 2019
1 year ago
Chiron is a B2B AI-driven platform for chronic disease management for both healthcare payers and providers. Our proprietary AI models fuse patient-reported outcomes, wearable biometrics, and longitudinal EHR data to continuously learn what works for each individual and deliver hyper-personalised, evidence-based self-management interventions, whilst adapting in real-time to health data changes. Chiron is designed to be patient-led but clinically integrated, fitting directly into clinical workflows rather than sitting outside them - reducing pressure on clinical services, significantly reducing costs and empowering patients to be the experts in their own care.
  • General Match
London (United Kingdom)20231 - 10$300.72KPre-Seed, $300.72K, November 22, 2024
1 year ago
Entspannung, Stressreduktion und Patientenberuhigung vor und während Behandlungen mit Virtual Reality
  • General Match
Neufahrn Bei Freising (Germany)20181 - 10Seed, September 28, 2018
1 year ago
Abi partners with healthcare innovators around the world to deliver on-demand access to healthcare professionals, empowered by cutting-edge AI. Our Next Generation Virtual Care platform delivers solutions to insurers, pharmaceuticals and digital health providers in over 40 countries.
  • General Match
Dublin (Ireland)201611 - 50$5.02MSeries A, $5.02M, March 30, 2023
1 year ago
Founded by Harvard-trained health economist Adam E. Block, PhD., Charm brings together decades of experience in data analytics, mixed-methods research, economic impact modeling, and health policy to conduct rigorous and timely industry research. We translate insights from academic journals, white papers, and public data sources to provide simple, clear, and evidence-based research that has an impact on the healthcare industry. Additionally, Charm provides expert witness and litigation support services, including damages modeling and supporting scoring simulation estimates for federal and other legislation.
  • General Match
New City (United States)20181 - 10Grant, January 23, 2025
1 year ago
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacturing, and sales of high-quality products exclusively for veterinarians worldwide. We are driven by our purpose of the sustainable improvement of local animal health and welfare. Dechra has sales and marketing organizations in 26 countries and market our products in 63 other countries worldwide through distributors or marketing partners. We see things from The Veterinary Perspective. Dechra continues to grow because we understand the challenges veterinarians face, and provide training, support, and information to help them help animals. Accessible science enables vets to better communicate with their clients. It’s this perspective that makes us a preferred supplier. Understanding customers is built into our business model. We give veterinarians what they need, from everyday evidence-based treatments to knowledge on rarer diseases. To ensure our growth, we’re not just an animal pharma company. We’re the veterinary professional’s pharma company. #TheVeterinaryPerspective Learn more about our company at Dechra-US.com.
  • General Match
Northwich (United Kingdom)1997501 - 1000Acquired, June 2023
1 year ago
WE ARE TECH FOUNDERS FUNDING TECH STARTUPS "Lets give you your first investment cheque" We are the champions of first money in (lets call it pre-seed) in MENA tech startups. Said differently, we want to give you your first investment cheque. If you are a MENA based startup, with a founding team that has complementary skill sets, then we sure want to talk to you, please apply for funding.
  • General Match
Riyadh (Saudi Arabia)201911 - 50Private Equity, March 1, 2021
1 year ago
In a world where Neurological disorders will affect 1 person in 3 and where the number of parkinson's patient will double in the next decade, reaching 13 million patients. Our mission is to empower clinicians with Biomarkers allowing them to identify Neurological Disorders (Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis) years before visible symptoms. Our ambition with NeuroClues is to become the brain's stethoscope. We are a team of seasoned MedTech entrepreneurs and doctors with as purpose to help our healthcare system cross the chasm of technology with pragmatic solutions. We work from anywhere but our base camps are in Louvain-la-Neuve, Belgium & Paris, France & NY, USA. We’re are looking to connect with individuals, companies, investors and Key Opinion Leaders that share our ambition and mission and that would be willing to partner with us in order to bring NeuroClues to the EU and US market.
  • General Match
Louvain-la-neuve (Belgium)202011 - 50$12.68MSeed, $5.33M, April 30, 2024
1 year ago
Bewältigung des Pflegenotstands durch KI-gestützte Lösungen für Rekrutierung und Mitarbeiterbindung im Gesundheitswesen
  • General Match
Berlin (Germany)20211 - 10Pre-Seed, December 10, 2021
1 year ago
  • General Match
Richland (United States)NA
1 year ago
The Algorithm of How Nature Can Heal the Human: Enbiosis Enbiosis Biotechnology is dedicated to unraveling the complexity of the gut microbiome and its impact on human well-being and disease by leveraging big data and AI. Our clinically proven, cloud-based technology offers personalized food recommendations and precision supplements for patients with gastrointestinal disorders. For Partners: Learn how you can integrate our SaaS product into your business to elevate your services. For Practitioners: Discover how our advanced microbiome analysis can enhance your patient care. Learn more about our solutions and how they can be integrated into your practice.
  • General Match
London (United Kingdom)201911 - 50$2.07MSeed, April 10, 2023
1 year ago
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
  • General Match
Basel (Switzerland)199610000+$2.49BIPO, May 19, 2000
1 year ago
Apax Partners LLP ("Apax") is a leading global private equity advisory firm. For over 50 years, Apax has worked to inspire growth and ideas that transform businesses. The firm has raised and advised funds with aggregate commitments of c.$80 billion. The Apax Funds invest in companies across three global sectors: Tech, Services, and Internet/Consumer. These funds provide long-term equity financing to build and strengthen world-class companies.
  • General Match
London (United Kingdom)1981201 - 500Debt Financing, April 1, 2023
1 year ago
We create intelligent digital health solutions that facilitate decision making in clinical practice. Our goal is to improve lives of children and their families, avoid unnecessary hospital stays and reduce health care costs.
  • General Match
Regensburg (Germany)202011 - 50$4.45MVenture - Series Unknown, September 10, 2024
1 year ago
At 80 Beats, we assist professionals to measure what matters, prevent cardiovascular events, improve diagnosis and therapy. Together, we can reshape the future of cardiovascular health, beat by beat. Visit www.80beatsmedical.com to learn more!
  • General Match
Berlin (Germany)200311 - 50NA
1 year ago
Qureight is a clinical data analytics company based in Cambridge UK. Working with healthcare institutions, technology companies and the pharmaceutical industry our platform allows the realisation of new endpoints in clinical data.
  • General Match
Cambridge (United Kingdom)201811 - 50$11.16MSeries A, $8.45M, April 16, 2024
1 year ago
Quantum-Mechanics and Machine Learning Drug Discovery. Pharmacelera develops proprietary Computer-Aided Drug Design software and provides access to its technology through flexible licensing options and computational chemistry services. The methodology mines an unexploited chemical space, finding starting points with larger chemical diversity and improving the creativity of chemists. The technology is based on accurate Quantum-Mechanics algorithms, Machine Learning and High-Performance Computing (HPC) and it derives from more than 25 years of research. Pharmacelera helps companies in Target Identification, Hit-Identification, Hit-to-Lead and Lead Optimization drug discovery stages by finding novel hits, improving ligand binding properties (ADME, Tox, ...), obtaining insights of ligand / receptor interactions and identifying original backup compounds. Learn more on how to de-risk your drug discovery project by emailing us at contact@pharmacelera.com or by visiting our webpage at www.pharmacelera.com
  • General Match
Barcelona (Spain)201511 - 50$11.15MVenture - Series Unknown, $7.11M, February 18, 2026
1 year ago
Clinical trials take 11 years and cost $6.2B to bring a drug to market. 57% face costly protocol amendments that add months of delay. We're changing that. Aika is the first explainable AI assistant purpose-built for clinical protocol design, specialized with 560,000+ real trials to help biotech, pharma and CROs design smarter protocols faster. The impact: → 50% faster protocol development → $200K-$400K saved per avoided amendment → Regulatory-ready outputs from day one Every recommendation is backed by verifiable sources. Every decision stays with clinical experts. Faster trials don't mean riskier ones. With Aika, they mean smarter ones. Built by clinical experts, for clinical experts.
  • General Match
Barcelona (Spain)202411 - 50$61.53MSeries A, $51.99M, February 2, 2026
1 year ago
iThera Medical developed and marketed biomedical imaging systems based on a novel technology called Multispectral Optoacoustic Tomography (MSOT). MSOT utilizes the photoacoustic effect to visualize and quantify anatomical, functional and molecular information, in vivo, in deep tissue and in real time. Today, MSOT allows the study of disease processes on a molecular level as well as the analysis of pharmacokinetic and biodistribution properties for new substances in small animals. Recently, MSOT has been translated for clinical use and promises to become a valuable diagnostic tool for a variety of diseases, including melanoma, inflammatory bowel disease, neuromuscular disease, and breast cancer. Due to lack of continued funding, Thera Medical had to close operations in August 2025.
  • General Match
München (Germany)201011 - 50$42.35MSeries D, $13.79M, December 21, 2022
1 year ago
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact. Recruitment Fraud Alert Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit. We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.
  • General Match
San Rafael (United States)19971001 - 5000$4.24BIPO, $58.50M, July 26, 1999
1 year ago
Founded in 2020 to revolutionize healthcare with the medical check-up and telehealth Medicube X™ eHealth Stations. MedicubeX aims to prevent cardiovascular diseases and diabetes by building autonomous self-measurement and telehealth kiosks. The Medicube X™ eHealth Station is a revolutionary innovation that enables monitoring of vital signs and CVD risk factors with high-quality remote video appointments. This allows most preventive interventions to be performed early, before problems develop. The Medicube X™ eHealth Station is an essential tool for managing the health of your patients.
  • General Match
Helsinki (Finland)20201 - 10$9.67MEquity Crowdfunding, $3.91M, November 6, 2025
1 year ago